Introduction {#Sec1}
============

In the past decade, intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have been successfully used in the treatment of several retinal neovascular diseases which were incurable not long ago. Ranibizumab and bevacizumab were the two most extensively used anti-VEGF drugs. Recently, aflibercept and conbercept, two new anti-VEGF agents have been developed. Owning to the alteration of the drug structure, the novel anti-VEGF drugs are capable of combining more molecular targets and present higher affinity to the angiogenesis promoting factors^[@CR1],\ [@CR2]^. Clinically, the new drugs make it possible to prolong the interval between multiple injections^[@CR3]^, are effective in some patients non-responsive to ranibizumab and bevacizumab^[@CR3],\ [@CR4]^, and even work in some severe patients with increased dosage. With a similar structure and effect to aflibercept, the newest anti-VEGF drug conbercept is a recombinant fusion protein composed of the second Ig domain of VEGFR1 and the third and fourth Ig domain of VEGFR2 to the constant region (Fc) of human IgG1. It is designed as a receptor decoy with high affinity for all VEGF isoforms and PlGF^[@CR1],\ [@CR5],\ [@CR6]^.

Although clinical trials have proved anti-VEGF drugs exhibit satisfactory safety in many neovascular retinal diseases, patients undergo intravitreal injections still suffer from some unwanted adverse events, even if the occurrence is low. Moreover, long-term repeated injections increase the risk of the small-probability ocular side effects^[@CR7],\ [@CR8]^. In addition to the adverse events that caused directly by the injection procedure, some side effects may be associated with the drugs themselves. These drug-related side effects include endophthalmitis^[@CR9]^, increase of intraocular pressure^[@CR7]^, retinal toxicity, and decrease of retinal function^[@CR7],\ [@CR10]^. It has been reported that bevacizumab may lead to an increase of intraocular and systemic concentrations of IL-6 and IL-8 in patients^[@CR11],\ [@CR12]^ and a loss of retinal ganglion cells (RGCs) in rats^[@CR13]^. Significant reduction of electroretinogram (ERG) a-wave and b-wave amplitudes in isolated bovine retinas after application of aflibercept has been reported, suggesting the drug might also affect retinal function^[@CR14]^.

The improved anti-VEGF effect of aflibercept and conbercept may be attributed to expandation of their targets and increase of affinity. In addition to blocking VEGF-A receptor as ranibizumab and bevacizumab do, both aflibercept and conbercept combine VEGFB and placental growth factor (PlGF), which promote neovascularization and permeability of the blood vessel. However, VEGF-B and PlGF are involved in normal physiological functions^[@CR15],\ [@CR16]^. There are increasing concerns with regard to whether blocking these targets may cause any unwanted side effects. In addition, PlGF exerts a protective effect on retinal neuronal cells^[@CR16]^ but it is still unknown whether it is an indispensable protective factor in the retina. Thus, one can never overemphasize the importance of the safety issue of the new agents, especially the safety concerns may be exaggerated in a diseased retina^[@CR17]^.

We studied whether high dosage and high frequency intraocular application of conbercept would cause unwanted ocular adverse effects. The affinity, pharmacokinetic and systemic tolerability of intravitreal injection of conbercept in rabbit has been studied^[@CR18]^. By using the same model, we evaluated the safety of intraocular administration of conbercept *via* morphological, functional and biological assessments. We also studied the retinal proteomics in the conbercept treated eyes.

Results {#Sec2}
=======

Intraocular pressure {#Sec3}
--------------------

The averaged IOPs (Fig. [1](#Fig1){ref-type="fig"}) after a single injection of PBS, or 0.2, 0.5, 2.0 mg of conbercept were 14.4 ± 1.3, 14.7 ± 2.2, 14.2 ± 1.9 and 15.1 ± 1.4 mmHg at day 4; 15.7 ± 1.8, 16.2 ± 2.4, 15,2 ± 1.3 and 15.8 ± 2.3 mmHg at day 7; 16.0 ± 2.0, 15.6 ± 1.8, 16.2 ± 1.9 and 16.9 ± 2.2 mmHg at day 14. The IOPs of the six-injection F and G groups were 15.3 ± 2.4 and 15.9 ± 1.9 mmHg on the 7^th^ day after the final weekly-injection. There was no significant difference (*p* \> 0.05, n = 6) in IOP after the single injection of 0.2, 0.5, 2.0 mg and the six weekly injections of 0.2 mg conbercept compared to the PBS groups.Figure 1The intraocular pressure (IOP) in rabbits after a single injection of 50 μL PBS, 0.2, 0.5 or 2.0 mg of conbercept and 6 multiple injections of 50 μL of PBS or 0.2 mg of conbercept. There was no significance in IOP among the conbercept-injected groups and the PBS-injected groups (*p* \> 0.05). The results are mean ± SD (n = 6).

Fundus examination {#Sec4}
------------------

After a single intravitreal injection of different doses of conbercept, no signs of abnormalities or inflammation was seen in the fundus (Fig. [2d--l](#Fig2){ref-type="fig"}) when compared to the PBS-injected groups (Fig. [2a,b and c](#Fig2){ref-type="fig"}). The vitreous was clear and the vascular pattern appeared normal. No vascular narrowing, dilatation or tortuosity, retinal detachment, hemorrhage or optic nerve head changes were seen. Similar results were found in the six-weekly conbercept-injected group (Fig. [2m](#Fig2){ref-type="fig"}) and the PBS-injected group (Fig. [2n](#Fig2){ref-type="fig"}).Figure 2Fundus photographs taken on the 4^th^, 7^th^, 14^th^ day after a single injection of 50 μL PBS (**a--c**) or 0.2, 0.5, or 2.0 mg of conbercept (**d--l**) and on the 7^th^ day after the 6^th^ multiple injections of 50 μL PBS (**m**) or 0.2 mg of conbercept (**n**). The results observed in the conbercept-injected groups mimic those in the PBS-injected groups.

ERG {#Sec5}
---

The representative ERG responses (Fig. [3A](#Fig3){ref-type="fig"}) of the conbercept- and PBS-injected rabbits and the amplitude-intensity profiles (Fig. [3B](#Fig3){ref-type="fig"}) were exhibited. The ERG waveforms and the amplitudes of the averaged a- and b-wave recorded under various stimuli in the conbercept-injected groups mimicked those in the PBS-injected groups. There was no significant differences (*p* \> 0.05, n = 5) between all the pairs in any of the recordings. The ERG showed no evidence of retinal functional damage after application of conbercept.Figure 3Dark- and light-adapted ERGs (**A**) and the amplitude *vs*. intensity profiles (**B**) obtained on the 4^th^, 7^th^, 14^th^ day after application of single intravitreal injections of 50 μL PBS or 0.2, 0.5, 2.0 mg of conbercept and on the 7^th^ day after the 6^th^ multiple injections of 50 μL PBS or 0.2 mg of conbercept. The amplitudes of a- and b-waves were not significantly different (*p* \> 0.05). The results were mean ± SEM (n = 5).

Histology {#Sec6}
---------

No apparent structural changes or sign of toxicity were observed in the conbercept-injected groups and the appearance of the retina were similar to the PBS control groups (Fig. [4](#Fig4){ref-type="fig"}). No sign of retinal degeneration, disorganization, thinning, cell loss, or hypocellularity was observed in these groups. The difference in the number of cells in the GCL in all the groups was not significant (*p* \> 0.05, n = 3). There was no significant difference in the thickness of the inner nuclear layer (INL) among all the groups (*p* \> 0.05, n = 3).Figure 4Retinal histology on the 4^th^, 7^th^, 14^th^ day after a single injection of 50 μL PBS or 0.2, 0.5, 2.0 mg of conbercept and on the 7^th^ day after the 6^th^ multiple injections of 50 μL PBS or 0.2 mg of conbercept. There was significant difference in the cell number in the ganglion ccell layer (GCL) and the thickness of inner nuclear layer (INL) (*p* \> 0.05). The results were mean ± SEM (n = 3). Scale bar: 50 μm.

TUNEL {#Sec7}
-----

TUNEL-positive cells were not seen in the GCL of any animals injected with different doses and frequencies of conbercept and PBS (Fig. [5](#Fig5){ref-type="fig"}). No significant difference in apoptotic cell was observed among the conbercept injected and the PBS-injected groups. In the NMDA-injected group which was the positive control, positive cells were seen in the GCL.Figure 5Detection of apoptotic cells in the ganglion cell layer (GCL) by TUNEL staining. Samples were collected on the 4^th^, 7^th^, 14^th^ days after a single injections of 50 μL PBS or 0.2, 0.5, 2.0 mg of conbercept and on the 7^th^ day after the 6^th^ multiple injections of 50 μL PBS or 0.2 mg of conbercept. No positive cells were observed in the GCL in the conbercept- and PBS-injected groups. TUNEL-positive cells were seen in the GCL and INL in the NMDA-injected eyes on the 7^th^ day after injection. Scale bar: 50 μm.

ELISA {#Sec8}
-----

Aqueous humor was collected at day 4, 7, 14 after a single intravitreal injection of different doses of conbercept or 50 μL of PBS and at day 7 after the 6^th^ weekly-injection of 50 μL PBS or 0.2 mg conbercept. The differences of the IL-6, IL-8 and TNF-α protein expression among the conbercept groups and the PBS groups was not significant (*p* \> 0.05, n = 4) (Fig. [6](#Fig6){ref-type="fig"}). The concentrations of the cytokines in the LPS-injected group which served as a positive control were higher than those of the other groups (*p* \< 0.001, n = 3\~4).Figure 6Protein levels of IL-6, IL-8 and TNF-α in the aqueous humor. Samples were collected on the 4^th^, 7^th^, 14^th^ day after single injection of 50 μL PBS or 0.2 mg, 0.5 mg, 2.0 mg of conbercept and on the 7^th^ day after the 6^th^ multiple injections of 50 μL PBS or 0.2 mg of conbercept as measured by ELISA. Positive control was collected 24 hours after injection of 100 μg of LPS. No statistically significant difference was found among the conbercept-injected groups and the PBS-injected groups. The protein levels of the three inflammation cytokines in the LPS-injected groups were significantly higher than all the other groups (*p* \< 0.001). The results are mean ± SEM (n = 3\~4). ^\#^Undetectable.

Proteomics analysis {#Sec9}
-------------------

Using the TMT quantitative mass spectrometry, a total of 6042 proteins were quantified from the rabbit retina on the 4^th^, 7^th^ and the 14^th^ day after intravitreal injection of 0.5 or 2.0 mg conbercept. Compared with the untreated control eyes, 250 proteins presented changes greater than 2 folds at either dosages or time point in the conbercept-injected eyes. Among them as shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, 50 proteins were up-regulated, 57 were down-regulated and the rest 143 proteins showed inconsistent changes at different times or dosages.Table 1Significantly up-regulated proteins after intravitreal injection of conbercept.Accession numberGene symbolProtein nameFold changeDay 4--0.5 mgDay 4--2.0 mgDay 7--0.5 mgDay 7--2.0 mgDay 14--0.5 mgDay 14--2.0 mg655884547FLT1vascular endothelial growth factor receptor 13.853.322.5718.353.466.73655833765MKRN2probable E3 ubiquitin-protein ligase makorin-2 isoform X52.101.572.686.632.994.52655855155NFKBIZ, MailNF-kappa-B inhibitor zeta isoform X24.041.573.086.367.891.35291405684YPEL2protein yippee-like 21.042.713.273.643.322.54655826988LOW QUALITY PROTEIN: 39 S ribosomal protein L20, mitochondrial-like3.611.113.403.202.923.28655841362KLHDC3kelch domain-containing protein 31.203.442.803.083.781.35655879793DLGAP3LOW QUALITY PROTEIN: disks large-associated protein 31.141.632.573.051.831.54655878481RC3H2roquin-2 isoform X41.971.951.562.991.581.86655846130BCANbrevican core protein3.233.071.972.802.962.45655834754RBM15Bputative RNA-binding protein 15B1.601.682.872.803.383.77291389567ZFC3H1zinc finger C3H1 domain-containing protein2.412.291.502.691.761.31655600655VPS13Avacuolar protein sorting-associated protein 13 A1.201.571.882.561.791.35315360675EPT1, SELI\*ethanolaminephosphotransferase 11.201.571.892.531.961.35655901171maestro heat-like repeat-containing protein family member 12.261.681.892.521.211.65655837568RNA-binding protein 48-like1.432.111.802.391.451.96655866221DNAJB12LOW QUALITY PROTEIN: dnaJ homolog subfamily B member 121.622.122.292.341.401.49129270090CRYAA\*alpha-crystallin A chain1.881.001.792.331.881.19655787703CMTM4CKLF-like MARVEL transmembrane domain-containing protein 41.141.221.712.202.001.16655834907BAP1ubiquitin carboxyl-terminal hydrolase BAP11.261.012.742.182.503.44655882768CRYBB1beta-crystallin B11.931.282.142.122.021.55655862947GATMLOW QUALITY PROTEIN: glycine amidinotransferase, mitochondrial1.201.571.772.093.171.35291416535UVSSAUV-stimulated scaffold protein A, partial1.221.371.702.071.101.53655883513LOW QUALITY PROTEIN: carbonyl reductase \[NADPH\] 1-like2.082.001.842.041.821.59655896223FAM118Aprotein FAM118A1.791.432.422.032.041.55655850611retinal-specific ATP-binding cassette transporter-like1.731.952.202.002.021.88655739906BAZ2ALOW QUALITY PROTEIN: bromodomain adjacent to zinc finger domain protein 2 A2.101.491.641.961.671.89126723630LGALS3\*galectin-31.352.011.461.942.221.65291387457SRA1steroid receptor RNA activator 11.101.461.321.931.812.39655846332GBAglucosylceramidase isoform X22.261.651.661.861.651.36655857145BMPR1Bbone morphogenetic protein receptor type-1B isoform X22.352.574.931.855.112.57655872717ABCA5ATP-binding cassette sub-family A member 5 isoform X22.161.552.171.832.272.05655752526CDK17cyclin-dependent kinase 172.171.571.421.762.341.35655771130SAMD4Bprotein Smaug homolog 21.201.572.131.761.951.35655858544PCDH10protocadherin-10 isoform X21.502.181.721.671.591.23655842878CEP57L1centrosomal protein CEP57L1 isoform X51.211.551.331.661.383.59655605232SORBS2sorbin and SH3 domain-containing protein 2 isoform X91.612.242.231.601.121.84655841271TREML2trem-like transcript 2 protein9.551.572.511.592.811.35291400631ATPase inhibitor, mitochondrial-like1.712.092.141.581.944.75655727731LETMD1LETM1 domain-containing protein 1 isoform X22.532.271.791.571.831.35291406313MAPTmicrotubule-associated protein tau isoform X115.271.503.981.482.584.30291399405MRTO4mRNA turnover protein 4 homolog1.361.202.301.451.221.59655890274OGG1N-glycosylase/DNA lyase1.861.571.921.381.882.89291410889PGER6prostaglandin-E(2) 9-reductase1.242.201.841.371.111.88655835184PXKPX domain-containing protein kinase-like protein isoform X41.131.672.081.272.331.10655601008APOA1apolipoprotein A-I isoform X11.112.851.091.241.341.31655864723ARPP19cAMP-regulated phosphoprotein 191.141.401.221.201.222.06655875742PCSK1NproSAAS1.241.761.751.171.832.05291405564ASIC2acid-sensing ion channel 21.591.682.171.151.141.02147903853ATP2A1, ATP2A3 SERCA1a\*sarcoplasmic/endoplasmic reticulum calcium ATPase 12.091.081.251.141.111.28291398822PARS2probable proline--tRNA ligase, mitochondrial1.751.582.151.111.401.06\*Means the proteins are not predicted proteins. Table 2Significantly down-regulated proteins after intravitreal injection of conbercept.Accession numberGene symbolProtein nameFold changeDay 4--0.5 mgDay 4--2.0 mgDay 7--0.5 mgDay 7--2.0 mgDay 14--0.5 mgDay 14--2.0 mg655828813RAPH1ras-associated and pleckstrin homology domains-containing protein 1−0.77−0.44−0.88−0.90−0.74−0.96291416104RGS8regulator of G-protein signaling 8−0.87−0.83−0.80−0.89−0.84−0.39291406868PIK3IP1phosphoinositide-3-kinase-interacting protein 1−0.20−0.40−0.81−0.89−0.95−0.23655603509LRRC4C LRRC4leucine-rich repeat-containing protein 4 C−0.93−0.38−0.98−0.88−0.97−0.52291384766MPPED2metallophosphoesterase MPPED2−0.58−0.25−0.42−0.88−0.93−0.46291382897TEX10testis-expressed sequence 10 protein−0.51−0.67−0.84−0.88−0.86−0.27655886298ZNF629zinc finger protein 629−0.73−0.49−0.95−0.84−0.80−0.94291403838MAP4K5mitogen-activated protein kinase kinase kinase kinase 5−0.70−0.44−0.90−0.82−0.89−0.80655876071SPIN3spindlin-3−0.50−0.15−0.63−0.82−0.91−0.98655896069MED15mediator of RNA polymerase II transcription subunit 15 isoform X3−0.36−0.46−0.54−0.82−0.71−0.63655605182SNX25sorting nexin-25−0.12−0.38−0.63−0.77−0.83−0.24655633237DMXL1LOW QUALITY PROTEIN: dmX-like protein 1−0.68−0.42−0.82−0.77−0.58−0.68291402173SIPA1L2signal-induced proliferation-associated 1-like protein 2−0.98−0.41−0.88−0.76−0.99−0.84291408938MED4mediator of RNA polymerase II transcription subunit 4−0.54−0.40−0.66−0.74−0.38−0.55655869905UBE2G1ubiquitin-conjugating enzyme E2 G1−0.51−0.36−0.86−0.74−0.75−0.54655889686DNAJC16dnaJ homolog subfamily C member 16 isoform X2−0.71−0.67−0.48−0.71−0.77−0.51655837812Friend virus susceptibility protein 1-like−0.61−0.72−0.48−0.66−0.49−0.67655899144PGS1LOW QUALITY PROTEIN: CDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase, mitochondrial−0.44−0.35−0.73−0.62−0.61−0.62655842073MB21D1cyclic GMP-AMP synthase−0.63−0.57−0.11−0.61−0.45−0.70655600047DDX58probable ATP-dependent RNA helicase DDX58 isoform X2−0.47−0.91−0.43−0.60−0.66−0.80655901439ras-related protein Rab-9A-like−0.48−0.63−0.87−0.59−0.92−0.96655875606CDK16cyclin-dependent kinase 16 isoform X7−0.34−0.55−0.83−0.57−0.22−0.70655847855COL11A1collagen alpha-1(XI) chain isoform X1−0.60−0.55−0.50−0.56−0.82−0.46655844088RMND1required for meiotic nuclear division protein 1 homolog isoform X2−0.32−0.41−0.71−0.54−0.64−0.35655902770interferon-induced GTP-binding protein Mx1−0.53−0.96−0.47−0.53−0.57−0.85655828284STAT1signal transducer and activator of transcription 1-alpha/beta−0.51−0.89−0.50−0.53−0.60−0.92291384499RRP8ribosomal RNA-processing protein 8−0.74−0.53−0.87−0.51−0.83−0.38655600642RFKriboflavin kinase−0.46−0.77−0.56−0.50−0.49−0.50655871198KRT15keratin, type I cytoskeletal 15−0.59−0.92−0.44−0.49−0.88−0.88655877487ARMCX2armadillo repeat-containing X-linked protein 2−0.97−0.68−0.91−0.49−0.81−0.34655895404DDX55ATP-dependent RNA helicase DDX55 isoform X2−0.81−0.46−0.61−0.49−0.76−0.732914092741,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial−0.91−0.74−0.67−0.44−0.75−0.64291402773ITGA11integrin alpha-11−0.57−0.74−0.38−0.44−0.67−0.64291389217KRT1keratin, type II cytoskeletal 1−0.67−0.78−0.40−0.44−0.82−0.78298919207RLA-A3\*MHC class I antigen-like precursor−0.32−0.55−0.39−0.40−0.46−0.77655883687cytosolic carboxypeptidase 1−0.26−0.43−0.59−0.40−0.71−0.30284005498AFF4, RA_m002_jsmFBA6Br\*AF4/FMR2 family member 4−0.63−0.36−0.52−0.40−0.37−0.41291389201keratin, type II cytoskeletal 6A-like−0.45−0.45−0.38−0.38−0.70−0.83291394553OSBPL3oxysterol-binding protein-related protein 3−0.44−0.49−0.23−0.37−0.41−0.61655812471serine/arginine repetitive matrix protein 3-like−0.42−0.55−0.51−0.33−0.62−0.47655730595KRT72keratin, type II cytoskeletal 72−0.58−0.71−0.49−0.33−0.82−0.74655897183CLASRPCLK4-associating serine/arginine rich protein isoform X2−0.48−0.62−0.51−0.32−0.38−0.26655603057PRKRIR52 kDa repressor of the inhibitor of the protein kinase−0.93−0.17−0.80−0.32−0.73−0.39655840152C12H6orf47uncharacterized protein C6orf47 homolog−0.31−0.32−0.28−0.31−0.20−0.32291389221KRT3, CK-3, K3keratin, type II cytoskeletal 3−0.53−0.74−0.35−0.31−0.87−0.55291406083keratin, type I cytoskeletal 14−0.44−0.39−0.33−0.30−0.60−0.70655730654KRT2LOW QUALITY PROTEIN: keratin, type II cytoskeletal 2 epidermal−0.60−0.91−0.32−0.29−0.80−0.60126722900\*lipophilin AL precursor−0.29−0.25−0.41−0.29−0.26−0.38655891028LOW QUALITY PROTEIN: D-dopachrome decarboxylase-like−0.59−0.24−0.90−0.27−0.26−0.38291393010LACC1laccase domain-containing protein 1−0.33−0.38−0.11−0.26−0.26−0.36126722998\*lipophilin CL2 precursor−0.21−0.26−0.37−0.25−0.29−0.50291389193KRT85keratin, type II cuticular Hb5−0.23−0.22−0.22−0.22−0.48−0.22291404267SLC25A16graves disease carrier protein−0.25−0.32−0.66−0.19−0.54−0.60655872869KRT34LOW QUALITY PROTEIN: keratin, type I cuticular Ha4−0.22−0.20−0.17−0.18−0.32−0.19655879141UBL3ubiquitin-like protein 3−0.18−0.26−0.60−0.15−0.44−0.63291407186MAP7D2MAP7 domain-containing protein 2 isoform X7−0.17−0.48−0.75−0.13−0.11−0.49291389187keratin, type II cuticular Hb6−0.21−0.14−0.18−0.13−0.27−0.20\*Means the proteins are not predicted proteins.^−^Means down-regulation. Table 3Significantly altered proteins with inconsistent changes after intravitreal injection of conbercept.Accession numberGene symbolProtein nameFold changeDay 4--0.5 mgDay 4--2.0 mgDay 7--0.5 mgDay 7--2.0 mgDay 14--0.5 mgDay 14--2.0 mg655874492TPCN1two pore calcium channel protein 11.682.401.162.88−0.941.24655846261RIT1GTP-binding protein Rit11.201.572.182.69−0.811.35655759055RPS19BP1active regulator of SIRT12.081.22−0.902.66−0.811.39655868318NSMCE4ALOW QUALITY PROTEIN: non-structural maintenance of chromosomes element 4 homolog A1.761.381.862.441.99−0.67655892261transmembrane protein 120B2.44−0.911.922.331.691.32291387997epidermal retinol dehydrogenase 21.091.541.832.192.21−0.93655884071HEATR3HEAT repeat-containing protein 32.18−0.921.312.141.68−0.80655870920SP2LOW QUALITY PROTEIN: transcription factor Sp2−0.911.14−0.662.11−0.71−0.67291411045PRR14proline-rich protein 141.16−0.502.382.10−0.883.31655880452THAP1THAP domain-containing protein 1 isoform X21.131.391.972.072.120.97655854410KALRNkalirin isoform X204.291.571.441.97−0.811.35655828138FKBP7peptidyl-prolyl cis-trans isomerase FKBP7−0.33−0.651.551.87−0.95−0.98291409542INTS5integrator complex subunit 5−0.811.282.201.781.681.02291410404KCNJ13, KIR7.1inward rectifier potassium channel 13 isoform X11.32−0.812.011.721.631.74655604456STIM2stromal interaction molecule 2 isoform X2−0.29−0.38−0.861.711.35−0.75291409135NR2F2COUP transcription factor 2 isoform X31.202.43−0.801.66−0.811.35655870532MRPS2328S ribosomal protein S23, mitochondrial isoform X21.203.511.641.64−0.813.85655886914TRIM4tripartite motif-containing protein 4 isoform X21.04−0.771.351.61−0.48−0.70291393060heterogeneous nuclear ribonucleoprotein A1-like−0.49−0.44−0.621.56−0.801.13291407324LANCL3lanC-like protein 3−0.661.53−0.721.53−0.451.11655605545STON1stonin-1 isoform X21.141.762.111.44−0.921.16655833182MOBPmyelin-associated oligodendrocyte basic protein1.301.49−0.691.422.011.16655603503C1H11orf74uncharacterized protein C11orf74 homolog−0.491.531.341.411.371.29655836760ZNF532zinc finger protein 532 isoform X32.501.122.211.38−0.641.03291403541RBM23probable RNA-binding protein 231.02−0.44−0.921.381.41−0.63655879659OSCP1protein OSCP1 isoform X41.29−0.371.371.34−0.611.22291383827TAGLNtransgelin1.45−0.47−0.371.311.601.73291401266C15H4orf32uncharacterized protein C4orf32 homolog−0.481.851.161.241.65−0.86291394485TIMM21mitochondrial import inner membrane translocase subunit Tim21−0.87−0.39−0.771.24−0.33−0.44655899294C3complement C3 alpha chain isoform X1, partial1.205.58−0.441.221.551.15284005533MAP1A\*microtubule-associated protein 1A1.281.962.141.21−0.481.34655601080PRDM10PR domain zinc finger protein 10 isoform X21.21−0.481.311.20−0.37−0.68655903015ARHGEF1LOW QUALITY PROTEIN: rho guanine nucleotide exchange factor 1−0.52−0.351.251.19−0.94−0.58655859423RGS7regulator of G-protein signaling 7 isoform X4−0.95−0.48−0.951.17−0.871.11655878265ZBTB43zinc finger and BTB domain-containing protein 431.03−0.47−0.911.162.52−0.41291383390C1H9orf41UPF0586 protein C9orf41 homolog1.06−0.54−0.961.14−0.98−0.47655832408PIBF1progesterone-induced-blocking factor 1−0.32−0.871.901.10−0.67−0.72291401111FGAfibrinogen alpha chain1.415.41−0.581.091.151.01291401007TIAM1T-lymphoma invasion and metastasis-inducing protein 1−0.86−0.45−0.861.091.11−0.95291406107NKIRAS2NF-kappa-B inhibitor-interacting Ras-like protein 2−0.47−0.781.051.07−0.711.29291401109FGBfibrinogen beta chain1.283.23−0.841.07−0.941.00655601664ALG9alpha-1,2-mannosyltransferase ALG9 isoform X2−0.76−0.54−0.931.06−0.82−0.13291395292PLCXD3PI-PLC X domain-containing protein 3−0.92−0.45−0.761.06−0.90−0.76291402327FBXO28F-box only protein 281.061.24−0.911.05−0.71−0.43291402543DSTYKdual serine/threonine and tyrosine protein kinase isoform X2−0.88−0.501.211.04−0.71−0.57655897677KDELR1ER lumen protein retaining receptor 11.28−0.86−0.491.04−0.681.08126723746ALB\*serum albumin precursor−0.912.52−0.861.041.241.23291413693MRPL4139S ribosomal protein L41, mitochondrial−0.78−0.331.281.041.131.32655902607phosphofurin acidic cluster sorting protein 2−0.711.31−0.731.03−0.86−0.38655883487PTPRELOW QUALITY PROTEIN: receptor-type tyrosine-protein phosphatase epsilon−0.49−0.64−0.611.03−0.691.52655856160FGGfibrinogen gamma chain isoform X21.153.46−0.721.02−0.981.00655862391TRIP4activating signal cointegrator 1 isoform X3−0.54−0.411.031.02−0.90−0.55655603017LOW QUALITY PROTEIN: transmembrane protease serine 13-like1.201.29−0.411.001.821.07655608615PSME4proteasome activator complex subunit 41.632.281.19−0.981.441.76655602331LIPT2putative lipoyltransferase 2, mitochondrial−0.79−0.78−0.40−0.981.38−0.68655805767RRN3RNA polymerase I-specific transcription initiation factor RRN3 isoform X21.161.062.04−0.97−0.711.40157787195TPM2\*tropomyosin 2 (beta)3.881.741.23−0.971.181.22655807516LOW QUALITY PROTEIN: THUMP domain-containing protein 1-like−0.97−0.461.00−0.96−0.96−0.59291389041PAK7serine/threonine-protein kinase PAK 7−0.74−0.491.11−0.96−0.901.09291406137NAGLUalpha-N-acetylglucosaminidase1.59−0.501.11−0.95−0.48−0.70655858943USP6NLLOW QUALITY PROTEIN: USP6 N-terminal-like protein−0.88−0.57−0.98−0.951.00−0.46655601434FXYD6FXYD domain-containing ion transport regulator 6 isoform X41.311.362.10−0.951.531.34126723638PAPSS2\*bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthase 2−0.38−0.761.50−0.941.231.54655897422uncharacterized protein C16orf74 homolog−0.50−0.621.11−0.94−0.86−0.48655801810RBFOX1RNA binding protein fox-1 homolog 1−0.62−0.461.05−0.94−0.61−0.83655879231RFC3replication factor C subunit 3 isoform X2−0.97−0.421.01−0.941.08−0.63655827806LRP2low-density lipoprotein receptor-related protein 22.131.57−0.80−0.94−0.811.35126723185ADCY10, SAC\*adenylate cyclase type 101.203.241.29−0.94−0.811.35291394610NOD1nucleotide-binding oligomerization domain-containing protein 11.201.572.70−0.94−0.811.35655897113ERCC1DNA excision repair protein ERCC-11.201.572.08−0.94−0.812.86291408033TCEAL5transcription elongation factor A protein-like 51.10−0.191.07−0.93−0.761.58291395159FAM134Bprotein FAM134B−0.90−0.371.20−0.921.031.04291403287ACTC1actin, alpha cardiac muscle 13.871.621.21−0.921.241.59291393596ELP6elongator complex protein 6 isoform X21.25−0.451.00−0.91−0.931.04291410032CBR3carbonyl reductase \[NADPH\] 3−0.62−0.45−0.99−0.91−0.941.47130493079TNNI2, TnI\*troponin I, fast skeletal muscle2.181.10−0.90−0.91−0.821.05655605874KCNIP3calsenilin isoform X31.04−0.47−0.87−0.90−0.961.25291400645QTRTD1queuine tRNA-ribosyltransferase subunit QTRTD1−0.561.68−0.40−0.90−0.87−0.55291412904\#N/Amitogen-activated protein kinase 8 isoform X11.28−0.331.14−0.891.271.37655895776SYVN1LOW QUALITY PROTEIN: E3 ubiquitin-protein ligase synoviolin1.38−0.31−0.98−0.87−0.93−0.55655663205ZNF346zinc finger protein 346 isoform X21.961.872.23−0.871.301.92655866440PBLDphenazine biosynthesis-like domain-containing protein isoform X2−0.802.202.75−0.872.386.72156119398MYL1\*myosin light chain 1/3, skeletal muscle isoform2.84−0.76−0.94−0.85−0.92−0.99291403770GEMIN2gem-associated protein 2 isoform X11.25−0.491.13−0.85−0.801.11291404856TRUB1probable tRNA pseudouridine synthase 11.211.712.13−0.84−0.771.36655853659HRGhistidine-rich glycoprotein−0.902.46−0.73−0.841.251.19655602610APBB1amyloid beta A4 precursor protein-binding family B member 1 isoform X6−0.88−0.45−0.59−0.841.99−0.87655861319GLRX2glutaredoxin 2 isoform X2−0.34−0.54−0.70−0.83−0.611.42291392203SMARCAL1SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 11.85−0.562.02−0.832.361.47655868632myosin-22.36−0.85−0.91−0.82−0.88−0.87291404152FUT11alpha-(1,3)-fucosyltransferase 111.031.05−0.91−0.81−0.80−0.39291416252EXOSC4exosome complex component RRP41−0.83−0.42−0.84−0.81−0.801.11291402469HSD11B1corticosteroid 11-beta-dehydrogenase isozyme 1−0.48−0.34−0.38−0.811.08−0.57655838173GPR98G-protein coupled receptor 981.19−0.471.52−0.801.171.44655599632STX17syntaxin-17−0.281.18−0.96−0.79−0.70−0.95655848676FUBP1far upstream element-binding protein 1 isoform X14−0.82−0.45−0.80−0.78−0.971.00655874201ANAPC5anaphase-promoting complex subunit 5 isoform X3−0.71−0.471.54−0.76−0.761.45655841323GLTSCR1LGLTSCR1-like protein isoform X2−0.99−0.48−0.71−0.751.07−0.84655889301PPLperiplakin−0.85−0.451.78−0.73−0.821.33291406958PPTC7protein phosphatase PTC7 homolog−0.46−0.411.04−0.73−0.87−0.87655758942MYBPC1myosin-binding protein C, slow-type, partial1.431.39−0.85−0.72−0.912.17291393095COMMD6COMM domain-containing protein 6 isoform X2−0.42−0.641.00−0.711.07−0.63291402968PIGBGPI mannosyltransferase 3−0.90−0.86−0.63−0.701.00−0.34655835568DALRD3DALR anticodon-binding domain-containing protein 3−0.871.221.40−0.691.373.34291396905SMPDL3Aacid sphingomyelinase-like phosphodiesterase 3a−0.76−0.43−0.93−0.661.011.26655895242ARHGEF10Lrho guanine nucleotide exchange factor 10-like protein3.28−0.911.14−0.65−0.821.36655902632TNNT1troponin T, slow skeletal muscle2.50−0.73−0.81−0.64−0.69−0.89655897791SH3BP5LSH3 domain-binding protein 5-like isoform X2−0.70−0.44−0.63−0.64−0.971.22655706784SLA2src-like-adapter 2−0.47−0.62−0.47−0.64−0.321.29655902451LAMA5LOW QUALITY PROTEIN: laminin subunit alpha-5−0.811.12−0.96−0.63−0.65−0.27291405504TMEM199transmembrane protein 1991.091.53−0.91−0.63−0.942.42655603581CRY2cryptochrome-21.13−0.361.01−0.63−0.831.31655729665KRT7LOW QUALITY PROTEIN: keratin, type II cytoskeletal 7−0.731.43−0.35−0.63−0.74−0.92655841393CUL9LOW QUALITY PROTEIN: cullin-91.35−0.79−0.52−0.631.53−0.48655894938PPP6R2serine/threonine-protein phosphatase 6 regulatory subunit 2−0.42−0.55−0.71−0.631.061.86291387257CSNK1G3casein kinase I isoform gamma-3 isoform X8−0.91−0.87−0.89−0.62−0.854.01291397177TFB1Mdimethyladenosine transferase 1, mitochondrial2.061.532.55−0.601.741.32291403160ZNF106, ZFP106zinc finger protein 1061.01−0.521.07−0.551.09−0.45655867504MRPL43LOW QUALITY PROTEIN: 39S ribosomal protein L43, mitochondrial1.191.13−0.96−0.531.03−0.32655765030MBLOW QUALITY PROTEIN: myoglobin−0.91−0.82−0.81−0.491.11−0.81655601432\#N/AFXYD domain-containing ion transport regulator 6 isoform X3−0.56−0.381.05−0.46−0.93−0.44291389209keratin, type II cytoskeletal 5 isoform X1−0.631.11−0.45−0.46−0.73−0.76655795749DHODHdihydroorotate dehydrogenase (quinone), mitochondrial−0.75−0.901.20−0.46−0.85−0.91291410767histone H2A type 1-H1.021.13−0.50−0.46−0.831.33655837047GPNMBtransmembrane glycoprotein NMB−0.581.19−0.39−0.46−0.76−0.66655886422MYLPFmyosin regulatory light chain 2, skeletal muscle isoform type 21.48−0.33−0.46−0.45−0.66−0.68291387979XKR4XK-related protein 4−0.57−0.74−0.87−0.451.041.54655771366NCCRP1F-box only protein 50 isoform X21.59−0.22−0.46−0.44−0.39−0.67655828240OSGEPL1probable tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrial isoform X21.01−0.73−0.94−0.44−0.38−0.63655871287KRT10keratin, type I cytoskeletal 10 isoform X2−0.601.25−0.33−0.43−0.92−0.71126723437ENO3, ENO1\*beta-enolase−0.68−0.661.07−0.43−0.451.68655835901\#N/Aband 4.1-like protein 3 isoform X19−0.771.211.46−0.41−0.951.45655831942LATS2serine/threonine-protein kinase LATS2 isoform X21.11−0.621.07−0.41−0.811.07655842035OGFRL1LOW QUALITY PROTEIN: opioid growth factor receptor-like protein 1−0.291.02−0.81−0.38−0.77−0.50655840529C12H6orf136uncharacterized protein C6orf136 homolog isoform X21.06−0.52−0.81−0.381.091.44291389971keratin, type I cytoskeletal 18−0.601.23−0.28−0.37−0.64−0.72291387122SMC6structural maintenance of chromosomes protein 61.03−0.60−0.31−0.36−0.31−0.52291404357hsc70-interacting protein−0.45−0.121.20−0.341.08−0.10655839030EMBembigin1.13−0.361.19−0.30−0.76−0.54655877350RAB9Bras-related protein Rab-9B1.231.791.67−0.281.99−0.41655901361ISG15ubiquitin-like protein ISG15−0.49−0.94−0.45−0.28−0.661.19655897078CD3EAPDNA-directed RNA polymerase I subunit RPA341.90−0.822.44−0.251.991.54655868318NSMCE4ALOW QUALITY PROTEIN: non-structural maintenance of chromosomes element 4 homolog A1.761.381.862.441.99−0.67^\*^Means the proteins are not predicted proteins.^−^Means down-regulation.

While most of the protein presented a fold change less than 3 folds, VEGF receptor 1 (VEGFR1) was the only protein that showed more than a 10-fold increase. In the 0.5 mg-injected group, the protein level of VEGFR1 was 3.85 times, 3.32 times and 2.57 times higher than the untreated group at the 4^th^, 7^th^ and 14^th^ day respectively. In the 2.0 mg-injected group it was 18.35 times, 3.46 times and 6.73 times higher. The complement C3 alpha chain isoform X1 partial 1 and fibrinogen alpha chain were the second highest increased proteins. It reached a 5-fold increase at day 7 in the 0.2 mg injected rabbits. The most decreased protein was cyclic GMP-AMP synthase, which decreased to 0.11 fold at day 14 in the 0.5 mg group.

We especially examined the changes of growth factors and proteins associated with inflammation and apoptosis. Neither of those proteins presented a fold change greater than 2. VEGF-B, PlGF and interleukins including interleukin-1 and interleukin-17 were not identified.

To better understand the functions of the differentially expressed proteins, we performed KEGG pathway analysis. The top 20 significant enriched pathway terms are shown in Fig. [7](#Fig7){ref-type="fig"}.Figure 7Differentially expressed proteins in the 6 study groups were enriched within 47 KEGG pathways compared to the untreated control group. The top 20 were presented.

Discussion {#Sec10}
==========

We investigated the safety of intraocular injection of high concentration and high frequency of a novel anti-VEGF agent conbercept in rabbit. No drug-related side effects were detected with IOP, fundus, retinal morphology and function assessments. No apoptotic cells were found in the retinal GCL in the conbercept injected eyes. We did not observe alternations of the major pro-inflammatory cytokines. Considering the high concentration and high frequency intravitreal injection did not cause unwanted side effects, we concluded that conbercept is well tolerated in rabbit in a short term observation.

Most of the transient elevation of IOP after intravitreal injection is believed to be caused by a sudden increase of vitreous volume and can recover within a few minutes to a few hours^[@CR19]^. However, it was reported that a limited number of AMD patients developed sustained elevation of IOP after single or repeated intravitreal injection of anti-VEGF drugs, which lasted from several weeks to even 1 or 2 years^[@CR20]^. The increase of IOP at long-term might be attributed to the drug itself. Nevertheless, we did not observed elevation of IOP among all the groups in our study.

Although overproduction of VEGF is deleterious, adequate concentrations of VEGF may be important for the eye to maintain normal functions including vascular development and neurons survival^[@CR21]--[@CR24]^. PlGF, a member of the VEGF family, also exerts a role in the protection of neuron in the retina^[@CR16]^. It was showed that potent inhibitors of all VEGF-A isoforms significantly diminished the protective effects of ischemic preconditioning on neurons. In addition, VEGF-A~120~ plays a supporting role in the survival of normal RGCs^[@CR22]^. It was also reported that multiple injections of high doses of up to 5.0 mg bevacizumab in rabbits would induce photoreceptors apoptosis at 1 week after injections^[@CR25]^. In a murine model, systemic administration of a viral vector expressing soluble VEGF receptor-1 led to a significant decline in ERG responses^[@CR26]^. Since conbercept is a multi-target VEGF blocker and binds all isoforms of VEGF-A, VEGF-B, and PlGF with high affinity, it arouses a concern whether it will lead to unwanted retinal neuron death and dysfunction. The number of GCL cells and the thickness of INL were not changed and no TUNEL-positive cells were seen in the RGC layer of the conbercept-injected groups. Functionally, the ERG waveforms were normal and the amplitudes of the a- and b-waves were similar to the PBS injected control group. We did not observed retinal and choroidal structural abnormalities under light microscope. Thus, our data are in agreement with other studies^[@CR27]^ that inhibition of VEGF or prolonged blockade of ocular VEGF receptors with conbercept would not cause morphological and functional damage to the retina.

Despite rarely happens, intraocular inflammation is a serious concern after intravitreal anti-VEGF treatment. We detected the protein expressions of IL-6, IL-8 and TNF-α in the aqueous humor of conbercept injected eyes. The levels of these inflammatory cytokines are similar to those in the PBS injected groups. Even though it is reasonable that the human fusion protein might cause inflammatory responses in rabbits, however, we did not observe such phenomenon.

We used 10-plex TMT-labeled proteomic quantification to analysis the variation of proteins in the retina of conbercept injected eyes. This technique has been demonstrated to be a powerful method to reach very large coverage of the proteome and to discover differentially expressed proteins (DEPs). Although the proteomic was based on a database of rabbit protein, it could help us to understand the protein alternation after intraocular administration of conbercept. To the best of our knowledge, this is the first study to explore DEPs in the retina after intraocular administration of an anti-VEGF drug.

Among 6042 proteins quantified, we identified 250 proteins (\~4%) altered by more than 2.0-fold or less than 0.5-fold with greater than 95.0% probability at least at one time point or dosage in the eyes applied with 0.5 or 2.0 mg conbercept at day 4, 7 or 14. The only protein that reached more than 10-fold increases was VEGFR1. It was not surprise since conbercept is a recombinant fusion protein contains several ligand binding domains including VEGFR 1. Increase of VEGFR1 should be a consequence of increase of exogenous conbercept. On the other hand, the data proved the efficacy of the assay.

Proteomic analysis did not show significant changes of cell death or inflammation associated proteins in the conbercept-injected eyes. No increase of cytokine, chemokine or neuroinflammation related proteins was observed. Compared with the untreated group, conbercept did not cause substantial changes of the expressions of growth factors. Although the complement C3 alpha chain isoform X1 partial 1 was detected, no any other related proteins were found. In the complement and coagulation cascades pathway, the levels of three fibrinogens were higher than the control but these proteins are also related with platelet activation. Thus, alternation of the complement C3 alpha chain isoform X1 partial 1 maybe associated with platelet activation, rather than inflammation. Platelet activation was detected as the most enriched pathway after conbercept injection. Fibrinogen alpha chain, fibrinogen beta chain and fibrinogen gamma chain isoform X2 increased at day 7 after injection. It has been shown that application of ranibizumab and bevacizumab may contribute to a risk of systemic thromboembolic events in elderly patients^[@CR28]^. Up-regulation of three fibrinogens after conbercept injection might raise a concern whether the proteins could be a potential risk factor. Research revealing the fibrinogen concentration in circulation would be helpful.

Mitochondrial adenosine triphosphate synthase (ATPase inhibitor) was up-regulated at all three time points. Bevacizumab was reported to show mild mitochondrial toxicity at clinically doses^[@CR29]^. Five mitochondrial proteins were altered significantly with four up-regulated involved in steroid biosynthesis, lipoic acid metabolism, pyrimidine metabolism, glycerophospholipid metabolism and one down-regulated in amino acid metabolism.

In the protein processing in endoplasmic reticulum, alpha-crystallin A chain was approximately 2-fold at day 4 and 1.5-fold increased at day 7 and 14 after injected with both dosages of conbercept. Alpha-crystalline is a member of heat shock protein family and acts as chaperones which is acknowledged to be a neuroprotective substance^[@CR30]^.

The Graves disease carrier protein (GDC) was down-regulated after conbercept injection at all three time points and decreased more than 5 folds in the 2.0 mg group at day 7. GDC is recognized in patients with active Graves disease (GD).

In the riboflavin (Vitamin B~2~) pathway, the expression of riboflavin (RF) kinase in the conbercept-injected groups decreased at all three time points. ATP:riboflavin kinase catalyzes the synthesis of cofactor flavinmononucleotide (FMN) by transforming riboflavin and ATP into FMN and ADP. RF is of physiological and nutritional importance in the maintenance of health of the retina^[@CR31]^.

There are inevitable limitations for this study. First, we injected recombinant human fusion protein into the rabbit eyes. The data was obtained form a rabbit database and the protein information could not be completely used to predict the outcome in human. Second, the cutoff we set for protein changes is 2 folds. Thus we can't exclude the possibility that a protein presents a fold change less than the threshold will not exert functional changes. However, since such investigation can't be duplicated in human subjects, the first retinal proteomic study in anti-VEGF injected eye still provide important information with regard to the molecular changes in the retina. Based on these data, it is practical to confirm whether the proteins are actually altered and to explore their significances. In addition, it is also possible to decide whether supplement treatments are necessary. For example, if it is confirmed that riboflavin kinase activity is lower in anti-VEGF injected eyes and consequently causes unwanted effect, it might be necessary to supply the patients with flavinmononucleotide.

We concluded that intravitreal injection of high concentration and high frequency of conbercept is well tolerated at least in a short-term in rabbit. Our study offers a comprehensive and intuitionistic overlook on the alteration of protein expression in the retina injected with conbercept. The data provided important information for the future clinical study and for designing therapeutic protocols.

Methods {#Sec11}
=======

Animals {#Sec12}
-------

All experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. The animals were fed with standard laboratory food and water in an air-conditioned room with a 12-hour light-dark cycle.

One hundred and eleven pigmented *Chinchila* rabbits, weighing 2 to 3 kg, were used. Only the right eye of each animal was injected and the left eye was untreated. Rabbits were randomized into nine groups. Group A (n = 3) did not receive any injection and was labeled as the blank. Group B (n = 27) received intravitreal injection of 50 μL of PBS and was labeled as control group. Groups C (n = 18), and D, E (n = 27 each) received intravitreal doses of 0.2, 0.5 and 2.0 mg/eye of conbercept on Day 0 respectively. Groups F and G (n = 6 each) received six weekly injections of 0.2 mg/eye of conbercept respectively. Groups H and I (n = 3 each) received 400 nmoles N-Methyl- D-Asparate (NMDA) and 100 μg lipopolysaccharide (LPS) respectively and were labeled as the positive control groups for TUNEL and ELISA essays.

The vitreous volume of a rabbit is approximately 1.5 mL and that of a human is about 5 mL. As the dose of 0.5 mg or less conbercept is frequently used in humans, the doses of 0.2, 0.5 and 2.0 mg for conbercept in rabbits are about 1.3, 3.3, and 13.3 times of that in human.

Intravitreal injection {#Sec13}
----------------------

Intravitreal injection was performed in sterile conditions. Rabbits were anesthetized with injection of 3% phenobarbital sodium solution (30 mg/Kg) through the ear vein. After corneal surface anesthesia with oxybuprocaine hydrochloride eye drop (Santen Pharmaceutical Co., Ltd, Osaka, Japan), a 27-gauge needle attached to a 1 mL syringe was introduced into the vitreous cavity 3.5 mm posterior to the superotemporal limbus. The needle tip was directed towards the center of the vitreous under direct visualization. The conbercept solutions or PBS (50 μL) was slowly administered into the vitreous. To prevent reflux, the needle was held in place for 30 seconds before withdrawal. At the end of the procedure, lincomycin hydrochloride eye drops were applied.

Intraocular pressure {#Sec14}
--------------------

At day 4, 7, 14 after the single intravitreal injection of conbercept (0.2 mg, 0.5 mg and 2.0 mg) or PBS, and at day 7 after the 6^th^ weekly-injection of conbercept (0.2 mg) or PBS, IOP was measured using a Schiotz tonometer (66 Vision Tech., Suzhou, China). Rabbits were anaesthetized with intraperitoneal injection of 1 mL/kg pentobarbital sodium. An average of five consecutive readings by the same observer was applied for analysis.

Fundus Photography {#Sec15}
------------------

The pupils were dilated with tropicamide eye drops (Shenyang Xingqi Pharmaceutical Co. Ltd, Shenyang, China) 30 minutes prior to imaging. The fundus photography of the rabbit eye was performed using a digital fundus camera system under anesthesia.

Electroretinogram {#Sec16}
-----------------

Electroretinogram (RetiMINER System, AiErXi Medical Equipment Co., Ltd., Chongqing, China) was recorded at day 4, 7, 14 after the single intravitreal injection and at day 7 after the 6^th^ weekly intravitreal injection. After dark adaptation, rabbits were anesthetized with pentobarbital sodium. Pupils were dilated and Burian-Allen corneal bipolar electrodes (Hansen Laboratory, Iowa City, Iowa) were applied as the corneal electrodes. The ground electrode was placed subcutaneously on the back. Dark- and light-adapted ERGs were recorded followed a previous procedure^[@CR32]^.

Histological Evaluation {#Sec17}
-----------------------

Animals were sacrificed with an injection of overdose sodium pentobarbital under deep anesthesia. Eyeballs were enucleated and half of the eyecup was fixed with 4% paraformaldehyde for 24 hours at room temperature^[@CR33]^. Tissues were embedded in paraffin and 4-μm sections were cut through the optic disc and stained with hematoxylin and eosin (HE). The images of each section were acquired. The number of cells in the GCL was counted in a region of 800 to 1500 μm from the center of the optic nerve head on both sides. The thickness of inner nuclear layer (INL) was measured in three areas at a distance of 500 to 1000 μm from the edge of optic disc. Four sections of each eye were measured, and data were averaged for each eye. All measurements and analysis were performed in a masked manner.

TUNEL {#Sec18}
-----

The terminal dUTP-mediated nick-end labeling (TUNEL) was performed to detect the apoptosis cells in the retina^[@CR33]^. Sections were mounted with fluorescein-FRAGEL media. Staining was performed according to the manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). Samples were permeabilized in 100 μL of 20 μg/mL proteinase K for 20 minutes, equilibrated with 100 μL of 1% TDT buffer for 30 minutes at room temperature and labeled with 60 μL TDT labeling reaction mixture for 1 hour at 37 °C. Sections were photographed and the TUNEL-positive cells were counted between 1000 to 1500 μm from the center of the optic disc on both sides in the GCL and INL.

ELISA {#Sec19}
-----

The concentrations of IL-6 (RayBiotech, Norcross, GA), IL-8 (R&D Systems, Minneapolis, Minnesota, CA) and TNF-α (RayBiotech) in 100 μL aqueous humor were determined according to the manufacturers' protocols^[@CR33]^. The absorbance at 450 nm wavelength was measured using a multifunction microplate reader (Molecular Devices).

Protein Extraction {#Sec20}
------------------

Retinas were isolated from the eyeball and frozen in liquid nitrogen and lysed using protein extraction buffer (8 [M]{.smallcaps} urea, 0.1% SDS) containing protease inhibitor cocktail (Roche, Indianapolis, IN, USA) on ice for 30 min and then centrifuged at 16,000 × g for 15 minutes at 4 °C. The supernatant was collected and protein concentration was determined by BCA assay kits (Pierce, Rockford, IL, USA).

TMT labeling and fractionation of labeled peptide {#Sec21}
-------------------------------------------------

Tandem mass tag (TMT) labeling was performed according to the manufacturer's instructions (Pierce). Proteins were precipitated by pre-chilled (−20 °C) acetone. After resuspension, proteins were digested overnight at 37 °C by using 2.5 μg of trypsin. One tube of TMT10 Label Reagent was added to each 100 μg sample and the reaction was carried out at room temperature for 1 hour. After labeling, ten tissue samples were combined for one measurement. For fractionation of the labeled peptides, samples were first lyophilized and reconstituted. A total of 40 fractions were collected which were concatenated to 20 fractions, vacuum dried and stored at −80 °C until further analysis.

LC-MS/MS Analysis {#Sec22}
-----------------

The LC-MS/MS analysis was carried out by Capitalbio Technology with a Q Exactive Mass Spectrometer (Thermo Scientific, San Jose, CA). Mass spectrometry analysis was performed in a data dependent manner with full scans (300--1,800 m/z) acquired using an Orbitrap mass analyzer at a mass resolution of 70,000 at 400 m/z in Q Exactive. Twenty most intense precursor ions from a survey scan were selected for MS/MS from each duty cycle and detected at a mass resolution of 35,000 at m/z of 400 in Orbitrap analyzer. All the tandem mass spectra were produced by higher-energy collision dissociation (HCD) method. Dynamic exclusion was set for 20 seconds.

Data analysis {#Sec23}
-------------

Proteome Discoverer software (Ver. 1.4, Thermo Scientific) was used to perform database searching against the *Oryctolagus cuniculus* database (46551 proteins) using the Sequest algorithms. Following settings were applied: precursor mass tolerance of 15 ppm, fragment mass tolerance of 20 mmu. Only high confident peptides with a global FDR \< 1% based on a target-decoy approach were included in the results. In the TMT quantitation workflow the most confident centroid method was used with an integration window of 20 ppm. For protein quantitation, only unique peptides were used to quantify proteins.

Enriched pathways were analyzed in a command-line program KOBAS 2.0. We used the whole genome as the default background distribution to identify the significantly enriched pathways statistically in a set of sequences. For each pathway that occurs in the set of genes, we counted the total number of genes in the set that were involved in the pathway. We then calculated the *p* value using a hypergeometric distribution. If a whole genome has *N* total genes, among which *M* are involved in the pathway under investigation, and the set of genes has *n* total genes, among which *m* are involved in the same pathway, the *p* value for the pathway is calculated as follows:

Because a large number of KEGG pathways are considered, multiple hypotheses tests are performed. To reduce the Type-1 errors (i.e. false positive discoveries), we performed an FDR correction with a default cutoff of 0.05^[@CR34]^.

Statistical Analysis {#Sec24}
--------------------

The IOP results were presented as mean ± SD and the other data were mean ± SEM. Statistical analysis was performed using the GraphPad Prism (GraphPad Prism 5, Inc., San Diego, CA, USA). The results were analyzed by one-way ANOVA followed by Bonferroni correction for multiple comparisons. *p* less than 0.05 was considered statistically significant.
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